In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

with approval in the EU anticipated in the coming weeks after the drug was backed by the EMA's human medicines committee. "In terms of the dynamics within the market, shares in first-line ...

Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: ...